We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Appointment of Commercial Director for RecipharmCobra Biologics
News

Appointment of Commercial Director for RecipharmCobra Biologics

Appointment of Commercial Director for RecipharmCobra Biologics
News

Appointment of Commercial Director for RecipharmCobra Biologics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Appointment of Commercial Director for RecipharmCobra Biologics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RecipharmCobra Biologics, has announced the appointment of Julian Hanak as Commercial Director. He brings a wealth of industry knowledge and experience having held senior positions in both contract service and biotech product development companies.

Julian will join the RecipharmCobra management team to build on the company’s growth in provision of manufacturing services for the biotech and biopharmaceutical industry.

Formerly at Renovo Plc (a biopharmaceutical drug discovery and development company), Julian gained senior management and commercial experience as Senior Vice President of Development.

Included in Julian’s key responsibilities was the oversight of CMO’s and direction of CMC activities during drug development.

Julian previously worked at RecipharmCobra Biologics’ Keele facility for 11 years progressing from Senior Scientist to Director of Production.

Julian also held positions at the National Institute for Medical Research, Bio Products Laboratory Ltd, and AstraZeneca.

Peter Coleman, CEO at RecipharmCobra Biologics, said: “I am delighted that Julian has decided to join RecipharmCobra Biologics as we look to strengthen our team’s depth of experience to expand our clinical production offering and to reach our goal as a leading commercial supplier for our customers. We all look forward to working with Julian to achieve these goals.”

Advertisement